Welcome to „BIOMED-LUBLIN" S.A.

  • Increase font size
  • Default font size
  • Decrease font size
1 2 3 4 5

DISTREPTAZA®

TRADE NAME OF THE PHARMACEUTICAL PRODUCT

DISTREPTAZA®
(Streptokinasum + Streptodornasum)

QUALITATIVE AND QUANTITATIVE COMPOSITION OF ACTIVE SUBSTANCES

One suppository contains active substances:

  1. Streptokinase - 15000 IU
  2. Streptodornase - 1250 IU

PHARMACEUTICAL FORM

Rectal suppositories 2g each

CLINICAL PARTICULARS

Indications

Distreptaza in suppositories is used in the following cases:

  1. Chronic adnexitis,
  2. Inflitrative/postsurgical lesions,
  3. Endometritis,
  4. Haemorrhoids of acute and chronic inflammatory state,
  5. Perianal abscesses and fistulas with an extensive inflammatory infiltration.
  6. Suppurative pericoxal cysts.

Posology and method of administration

After removing a suppository from the blister pack insert it well up into the rectum. The dosage is dependent on the type and level of exacerbation of the inflammatory state. Use according to the recommendations of a physician.

Dosage regimen in serious states:

  1. 3 x 1 suppository over the first 3 days
  2. 2 x 1 suppository over the following 3 days
  3. 1 x 1 suppository over the following 3 days.

Dosage regimen in less serious states:

  1. 2 x 1 suppository over 3 days
  2. 1 x 1 suppository over the following 4 days
  3. or 2 x 1 suppository over 2 days

The average quantity of suppositories applied in the treatment is 8 to 18. The average treatment lasts for 7 - 10 days.

Contraindications

The product should not be in contact with a recently crusted wound or with recently performed suturing, as it may cause the disengagement of the stitches followed by wound bleeding.

Special warnings and precautions for use

None.

Interactions with other medicinal products and other forms of interactions

Not observed.

Pregnancy and lactation

Distreptaza in suppositories should not be used in pregnant and breast feeding women.

Effects on ability to drive and use machines

The medicine does not cause psychophysical deficiency. No effects on the ability to drive or use machines have been observed.

Undesirable effects

Adverse reactions such as allergic reactions, rise in body temperature and an inclination to bleeding may be observed.

Overdose

The consequences of an overdose are not known.

PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: ATC code B 01 AD

Pharmacodynamic and pharmacokinetic properties

The product Distreptaza in suppositories contains two active substances: streptokinase and streptodornase.

Streptokinase is an activating agent of the human blood proenzyme called plasminogen, which under streptokinase influence transforms into plasmin, acting as a fibrinolytic agent in the human blood.

Streptodornase is an enzyme demonstrating the ability to dissolve viscous nucleoprotein mass, dead cells and pus, not affecting live cells and their physiological functions.

Distreptaza in suppositories is used as an independent medicinal product or auxiliary, whose activity facilitates much better access of antibiotics or chemotherapeutics to the focus of inflammation. The product decreases patients’ complaints and considerably shortens the period of treatment.

PHARMACEUTICAL PARTICULARS

Composition of the medicinal product and list of excipients.

One suppository contains:

  1. Active substances: streptokinase - 15000 IU streptodornase - 1250 IU

Excipients:

  1. paraffin oil 0.16 g
  2. Witepsol H 15 1.84 g

Incompatibilities

None.

Shelf life

In immediate packaging - 2 years.

Special precautions for storage

  1. Medicinal product should be stored at 2°C to 8°C.
  2. Do not freeze
  3. Medicinal product should be kept away from children.

Nature and contents of container

Cardboard box contains 1 blister pack with 6 suppositories.

Instruction for use

After removing from the blister pack insert suppository well up into the rectum.